TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Patients on the postpartum ward at University Hospital will be offered inclusion in the study if they are:~* healthy,~* 18-40 years old,~* delivered a healthy term infant,~* intend to breastfeed,~* desire Implanon as their method of contraception, and~* agree to be randomized to early versus standard postpartum insertion.~Exclusion Criteria:~* obstetric complications including anemia with hematocrit\<30,~* transfusion,~* infection,~* severe pregnancy induced hypertension,~* prolonged hospitalization,~* coagulopathy,~* liver disease,~* undiagnosed genital bleeding,~* or other relative contraindication to Implanon® insertion (known or suspected pregnancy, known, suspected, or history of breast cancer, or hypersensitivity to any of the components in Implanon®).~* Women taking drugs that are potent inducers of hepatic enzymes will also be excluded, including barbiturates, griseofulvin, rifampin, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, modafinil, protease inhibitors, and herbal products including St. John's Wort.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Early postpartum insertion
- 2 (Type: ACTIVE_COMPARATOR): Standard postpartum insertion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Female and male aged 18 and 65 years.~* At least 6 months of documented clinical diagnosis of asthma as defined by GINA 2012 or American Thoracic Society (Expert Panel Report 3 2007) prior to visit 1~* Stable asthmatics on SABA alone, on low dose ICS (200-400 µg budesonide corresponding) or on fixed combination of low ICS/LABA~* At the enrolment visit 1a, the visit baseline FEV1 must be ≥80 % of that predicted normal (NHANES III). For LABA patients the visit baseline FEV1 must be ≥80 % of that predicted normal (NHANES III) at both visit 1a and visit 1b. If not, the patient will be withdrawn from the study~* At the enrolment visits 1a or 1b (LABA patients only) and at the end of run-in period, visit 2, eligible patients should demonstrate an airway responsiveness to methacholine PC20 \<8 mg/mL. If not, the patient will be withdrawn from the study~* Capable of using Turbuhaler inhalation device as judged by investigator. Exclusion Criteria: Diagnosed with COPD or history of cystic fibrosis, bronchiectasis or other respiratory diseases~* Pregnancy, breast-feeding, lactation, or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures~* Conditions which could alter airway reactivity to methacholine (e.g. pneumonia, upper respiratory tract infection, viral bronchitis and/or sinobronchitis) within past six weeks~* Exacerbation due to asthma or change in asthma medication during the last 3 months prior to enrolment~* Night time awakenings due to asthma symptoms on 2 consecutive nights during the last 4 weeks prior to enrolment~* Smokers 6 months prior to the study start or with a history of smoking of more than 10 pack years (e.g. 20 cigarettes/day for at least 10 years, or 10 cigarettes/day for at least 20 years, or equal).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bricanyl Turbuhaler M2, Active (Type: ACTIVE_COMPARATOR): Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
- Bricanyl Turbuhaler M3, Active (Type: ACTIVE_COMPARATOR): Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
- Turbuhaler M2, Placebo (Type: PLACEBO_COMPARATOR): Placebo powder for inhalation
- Turbuhaler M3, Placebo (Type: PLACEBO_COMPARATOR): Placebo powder for inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with glaucoma and ocular hypertension~Exclusion Criteria:~* History of ocular surgery within 3 months~* Administration contradiction to timolol and dorzolamide

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): combination of dorzolamide hydrochloride and timolol maleate
- 2 (Type: ACTIVE_COMPARATOR): Concomitant use of dorzolamide hydrochloride and timolol maleate
- 3 (Type: ACTIVE_COMPARATOR): timolol maleate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18-75~2. HIV+~3. Clinically significant fatigue (score of 4.5+ on Fatigue Severity Scale, plus impairment on 1+ categories of Role Function Scale)~4. Fatigue duration for 3+ months~5. English-speaking~6. Able to give informed consent~7. Fecund women uses barrier method of contraception~Exclusion Criteria:~1. Primary care doctor does not approve of study participation~2. Unstable medical condition (e.g. liver failure;cirrhosis, new onset opportunistic infection \[O.I.\] in past month)~3. Untreated hypogonadism, except for men for whom testosterone replacement is medically contraindicated (serum testosterone below the reference range)~4. Untreated hypothyroidism (thyroid stimulating hormone \[TSH\] over 5 IUI/mL)~5. Untreated and uncontrolled hypertension~6. Clinically significant anemia (hematocrit \<30%)~7. Started testosterone or nandrolone in past 6 weeks~8. Started or changed an antiretroviral regimen in past 4 weeks if fatigue predated the change; otherwise, started or changed regimen in past 2 months~9. Untreated or under-treated major depressive disorder~10. Started antidepressant medication within past 6 weeks~11. Substance abuse/dependence (past 4 months)~12. Regular and frequent cannabis use (\> twice/week regularly)~13. Currently clinically significant suicidal ideation or Hamilton Depression Rating Scale (HAM-D) \>24~14. History or current psychosis or bipolar disorder~15. Pregnant or breastfeeding~16. Significant untreated insomnia (score \>3 on HAM-D insomnia items)~17. Currently taking psychostimulant medication or past nonresponse to modafinil~18. Has no alternative viable antiretroviral regimen after the current one~19. Left ventricular hypertrophy; mitral valve prolapse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Modafinil (Type: EXPERIMENTAL): Participants will take modafinil for 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will take placebo for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 18 and 65 years of age~* Diagnosed with current PTSD as defined by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5),~* For patients with a qualifying Index trauma(s) resulting in PTSD that occurred during military service, military contractor, Department of Homeland Security or law enforcement~* Willing and able to withdraw and refrain from specific therapies (ask PI)~* Use medically acceptable form of contraception (female only)~* Signed informed consent~Exclusion Criteria:~* Significant traumatic brain injury~* Severe depression~* Bipolar and psychotic disorders~* Increase risk of suicide~* Significant clinical (cardiac, systemic infection, drug/alcohol abuse) or laboratory abnormalities (including positivity for Hep B, Hep C, HIV)~* Unable to wash-out specific medications (ask PI)~* History of violent behavior within past 2 years, unrelated to work duties~* History of drug or alcohol abuse within past 6 months~* Positive illegal substance test~* Known hypersensitivity to cyclobenzaprine~* Others: seizure disorders, uncontrolled sleep apnea, BMI\>40~* Participation in an investigational study in past 30 days~* In the process of litigating for compensation for a psychiatric disorder~* Females that are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime.
- TNX-102 SL, 2.8 mg (Type: ACTIVE_COMPARATOR): 1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime.
- TNX-102 SL, 5.6 mg (Type: ACTIVE_COMPARATOR): 2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females 2 years and older~* Has a clinical diagnosis of Atopic Dermatitis (AD) according to the criteria of Hanifin and Rajka~* Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)~* Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1~* All female subjects of childbearing potential must use acceptable methods of contraception from the Screening Visit continuously until 30 days after stopping study drug~Exclusion Criteria:~* As determined by the study doctor, a medical history that may interfere with study objectives~* Unstable AD or any consistent requirement for high potency topical corticosteroids~* History of use of biologic therapy (including intravenous immunoglobulin)~* Recent or anticipated concomitant use of systemic or topical therapies that might alter the course of AD~* Recent or current participation in another research study~* Females who are breastfeeding, pregnant, or with plans to get pregnant during the participation in the study~* Participation in a previous AN2728 clinical trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AN2728 Topical Ointment, 2% (Type: EXPERIMENTAL): AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
- Matching vehicle control (Type: PLACEBO_COMPARATOR): Matching vehicle control, applied twice daily for up to 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 69 or older~* meets DSM-IV criteria for current unipolar major depression~* HRSD (17 item) score of 15 or higher~* Folstein Mini Mental Status exam score of 18 or higher~Exclusion Criteria:~* Lifetime diagnosis of any psychotic disorder or bipolar disorder~* alcohol or drug abuse within the past six months~* MATTIS Dementia Rating Score of 120 or less~* Contraindication to SSRI therapy~* Hyponatremia

- Gender: ALL
- Minimum Age: 69 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Primary open angle glaucoma or ocular hypertension~Exclusion Criteria:~* Patients at risk of progression of visual field loss~* Patients with severe visual field defect~* Patients with any diseases that preclude participation in this study for safety reasons

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo ophthalmic solution (Type: PLACEBO_COMPARATOR): Eyedrop
- DE-117 ophthalmic solution low (Type: EXPERIMENTAL): Eyedrop
- DE-117 ophthalmic solution high (Type: EXPERIMENTAL): Eyedrop
- Latanoprost ophthalmic solution 0.005% (Type: ACTIVE_COMPARATOR): Eyedrop

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written-informed consent.~* Subjects over 18 years of age, and less than 70 years old.~* Subjects with a definite, possible, or probable diagnosis of ALS, according to the revised El Escorial criteria.~* Subjects having experienced their first ALS symptoms within 18 months before recruitment/consent.~* FVC \> 70%~* Subjects must be medically suitable for study participation and of complying with all planned aspects of the protocol including blood sampling at the time of inclusion in the study.~Exclusion Criteria:~* Subjects with a clinically significant preexisting lung disease not attributable to ALS.~* Subjects with a diagnosis of other neurodegenerative diseases or diseases associated with dysfunction of the motor neurons that can confuse the diagnosis of ALS.~* Participation in other clinical trials, or the reception of any other investigational drug in the six months prior to the start of the study.~* Female subjects who are pregnant, currently breastfeeding, or attempting to conceive during the study.~* Difficult peripheral venous access precluding plasma exchange and inability to implement a viable alternative catheter to make continued performing plasma exchange visits according to protocol~* Any contraindication for plasma exchange or abnormal coagulation parameters according clinical criteria from apheresis team~* A history of frequent adverse reactions (serious or otherwise) to blood products.~* Hypersensitivity to albumin or allergies to any of the components of Albutein.~* Subjects that can not interrupt treatment with acetylsalicylic acid or oral anticoagulants~* Plasma creatinine \> 2mg/dl.~* Present a history of heart disease including ischemic heart disease or congestive heart failure.~* Presence of prior conduct disorders requiring pharmacologic intervention, with less than 3 months of stable treatment~* Any condition that complicates adherence to study protocol (illness with less than one year of expected survival, drug or alcohol abuse, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Albumin (Type: EXPERIMENTAL): Plasma exchange with Albumin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed 6 weeks of treatment and all required assessments on the final study visit (Visit 8) of Study D1050289 (NCT01143077).~Exclusion Criteria:~* Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or damage to property.~* Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see Appendix 3 for BMI determination).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female between 18 and 70 years old~2. Patients with histologic proved metastatic breast cancer, unsuitable to be treated locally.~3. Patients with Her-2 negative breast cancer(HER-2 negative or one plus by IHC test , if HER-2 two plus by IHC,FISH result should be negative)~4. Disease progression after anthracycline and/or taxane regimen therapy and candidate for capecitabine monotherapy~5. Patients previously treated by capecitabine containing regimen should response to the chemotherapy containing capecitabine and progressed at least 4 months after the last capecitabine treatment~6. Karnofsky score more than 70；ECOG 0\~2；~7. Normal functions with heart, liver,renal and bone marrow~8. WBC≥4×109/L；Hb≥90 g/L；plt≥100×109/L~9. Got ICF before enrollment~Exclusion Criteria:~1. Pregnant or breast-feeding women or positive serum pregnancy test~2. Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling~3. Participation in any investigational drug study within 4 weeks preceding treatment start.~4. Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer.~5. Serious uncontrolled intercurrent infections~6. Poor compliance

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- experimental arm (Type: EXPERIMENTAL): capecitabine and pseudomonas aeruginosa combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 2 months to \< 18 years old.~* Presence of ABSSSI warranting initial hospitalization.~* Presence of ABSSSI with measurable margins of erythema, that includes deeper and/or extensive soft tissue involvement, or requires significant therapeutic surgical intervention~Exclusion Criteria:~* Documented history of any hypersensitivity or allergic reaction to vancomycin, aztreonam, or any β-lactam antimicrobial~* Uncomplicated skin and soft tissue infections~* More than 24 hours of prior antimicrobial therapy ≤ 96 hours before randomization.~* Requirement for any concomitant systemic antimicrobial therapy~* History of seizures, excluding well-documented febrile seizure of childhood.~* Clinical signs or suspicion of meningitis

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ceftaroline fosamil (Type: EXPERIMENTAL): None
- Comparators (Type: ACTIVE_COMPARATOR): Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete